Firebrick Pharma Limited (AU:FRE) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Firebrick Pharma Limited has signed a Marketing Representation Agreement with Innorini Life Sciences to promote Nasodine Nasal Spray to healthcare professionals in Singapore. This strategic partnership allows Innorini to handle sales to clinics and hospitals, giving Firebrick a fixed revenue per unit sold. The agreement marks a significant step in Firebrick’s expansion into international markets, following their recent push for pharmacy distribution in Singapore.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue